Amphastar Pharma Q2 Adj $0.94 Beats $0.77 Estimate, Sales $182.39M Beat $170.94M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amphastar Pharma (NASDAQ:AMPH) reported strong Q2 earnings, with adjusted EPS of $0.94 beating the $0.77 estimate and sales of $182.39M surpassing the $170.94M estimate. This represents significant year-over-year growth in both earnings and sales.
August 07, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amphastar Pharma reported Q2 adjusted EPS of $0.94, beating the $0.77 estimate by 22.08%. Sales of $182.39M also surpassed the $170.94M estimate, showing a 25.17% year-over-year increase.
The significant beat on both EPS and sales estimates, along with strong year-over-year growth, is likely to positively impact Amphastar Pharma's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100